Mayo Clinic (Rochester)
Rochester, MN
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
EXCALIBER - Maintenance
Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
- CELMoD
- Randomization
- Post-Autologous Stem Cell Transplant
- Phase 3
Accepting patients
CA088-1005
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 1
- Has results
Accepting patients
MMSET Inhibitor
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- H3K36me2
- Phase 1
- Has results
Accepting patients
Etentamig
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
- CAR T Cell
- BCMA
- CD19
- Phase 1/2
- Has results
- Bispecific Antibody
- BCMA
- CD3
- Randomization
- Phase 2
Accepting patients
Linvoseltamab
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
Not yet accepting
DURGA-4
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- CAR T Cell
- CD19
- BCMA
- Randomization
- Phase 3
- T Cell Engager (TCE)
- Bispecific Antibody
- BCMA
- CD3
- Randomization
- High Risk
- Maintenance
- Phase 2
3 hidden based on your filters.Show All